Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.66 |
| ▸ | CCND1 | P24385 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15270782 | 0.95 | CDK4 (0.69) | CDK4CCND1LMNAHTTALDH1A1 | |
| SCHEMBL20378423 | 0.80 | HTT (0.61) | CDK4CCND1LMNAHTTALDH1A1 | |
| SCHEMBL31287386 | 0.79 | PLG (0.43) | CDK4CCND1 | |
| SCHEMBL4992403 | 0.78 | CDK4 (0.78) | CDK4CCND1LMNADRD2DRD4 | |
| SCHEMBL30701168 | 0.78 | CDK4 (0.78) | CDK4CCND1LMNADRD2DRD4 | |
| SCHEMBL5793841 | 0.77 | CDK4 (0.55) | CDK4CCND1LMNAHTTALDH1A1 | |
| SCHEMBL9358675 | 0.77 | CDK4 (0.63) | CDK4CCND1LMNAHTTALDH1A1 | |
| SCHEMBL11366447 | 0.76 | CDK4 (1.00) | CDK4CCND1LMNAHTTALDH1A1 | |
| SCHEMBL28236962 | 0.76 | CDK4 (0.81) | CDK4CCND1LMNADRD2DRD4 | |
| SCHEMBL10290564 | 0.76 | HTR2C (0.38) | CDK4CCND1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223631-A1 | METHODS AND KITS FOR DETECTION OF TARGETS USING PCR AND PADLOCK PROBES | APLEX BIO AB (SE) | 2025-07-10 | — | — | US | disclosed |
| US-11655504-B2 | High intensity labeled reactant compositions and methods for sequencing | Quantum-Si Incorporated (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230151407-A1 | A METHOD FOR MULTIPLEXED DETECTION OF A PLURALITY OF TARGET BIOMOLECULES | APLEX BIO AB (SE) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655504-B2 | High intensity labeled reactant compositions and methods for sequencing | NSUN2, FBL, DNMT3A | CDK4 3083/4885CCND1 4192/4885LMNA 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.